Multicenter phase II study of FOLFOX for metastatic colorectal cancer (mCRC) in Japan; SWIFT-1 and 2 study

Hepato-Gastroenterology

Volumn 56, Issue 94-95, 2009, Pages 1346-1353

  Nagata, Naoki ^a   Kondo, K ^b   Kato, T ^c   Shibata, Y ^d   Okuyama, Y ^e   Ikenaga, M ^f   Tanemura, H ^g   Oba, K ^h   Nakao, Akimasa ⁱ   Sakamoto, J ^j   Mishima, H ^f  

^a Kitakyushu General Hospital   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^c Mino Municipal Hospital   (Japan)

^d TOYOHASHI MUNICIPAL HOSPITAL   (Japan)

^e KYOTO FIRST RED CROSS HOSPITAL   (Japan)

^f OSAKA NATIONAL HOSPITAL   (Japan)

^g Gifu Municipal Hospital   (Japan)

^h KYOTO UNIVERSITY   (Japan)

ⁱ NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Chemotherapy; FOLFOX4 and mFOLFOX6 regimens; Metastatic colorectal cancer; Phase II study

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; JAPAN; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS;

EID: 71949103065     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Nordic Gastrointestinal Tumor Adjuvant Therapy Group: Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 10; 904-911:1992.
2. Scheithauer W, Rosen H, Kornek GV, et al: Randomised comparison of combination chemotherapy plus supportive care with supportive care alon in patients with metastatic colorectal cancer. Br Med J 306; 752-755:1993. (Pubitemid 23080053)
3. Simmonds PC: Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. Br Med J 321; 531-535:2001.
4. Poon MA, O'Connell MJ, Moertel CG, et al: Biochemical modulation of fluorouracil: evidence of signifi cant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7:1407-1418
5. O'Connell MJ: A phase III trial of 5-fluorouraccil and leucovorin in the treatment of advanced colorectal cancer. Canaer 1989; 63:1026-1030.
6. Kidani Y, Inagaki K, Tsukagoshi S: Examination of antitumor activities of platinum complexes of 1,2-diaminocyclohexane isomers and their related complexes. Gann 1976; 67:921-922 (Pubitemid 8027032)
7. Machover D, Diaz-Rubio E, de Gramont A, et al: Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fl uoropyrimidines. Ann Oncol 1996; 7:95-98. (Pubitemid 26051870)
8. Becouarn Y, Ychou M, Ducreux M, et al: A phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. J Clin Onco 1998; 18:2739-2744. (Pubitemid 28363039)
9. de Gramont A, Vignoud J, Tournigand C, et al: Oxaliplatin with high-dose leucovorin and 5-fl uorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997; 33:214-219. (Pubitemid 27117717)
10. Goldberg RM, Sargent DJ, Alberts SR, et al: A randomized controlled trial of fl uorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23-30.
11. de Gramont A, Figer A, Bonetti A, et al: Leucovorin and fluorouracil with or without oxaliplatin as fi rst-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-2947. (Pubitemid 30644117)
12. Tournigand C, Andre T, de Gramont A, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-237. (Pubitemid 41095086)
13. Shirao K, Matsumura Y, Yamada Y, Muro K, Gotoh M, Boku N, et al: Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors. Jpn J Clin Oncol 2006; 36:295-300. (Pubitemid 43997334)
14. Hyodo I, Shirao K, Boku N, Ohtsu A, Miyata Y, Nakagawa K, et al: Phase II trial and pharmacokinetic analysis of oxaliplatin (L-OHP) as second-line treatment in patients (patients) with metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2003 (abstr 1383).
15. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92(3):205-216. (Pubitemid 30099779)
16. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, et al: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil - leucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21:2059-2069
17. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23-30.
18. Kidani Y, Noji M, Tashiro T, et al: Antitumor activity of platinum(II) complexes of 1,2-diamino-cyclohexane isomers. Gann 71:637-643, 1980. (Pubitemid 10030519)
19. Rixe O, Ortuzar W, Alvarez M, et al: Oxzliplatin, tetraplatin, cisplatin, and carbolplatin: spectrum of activity in drug-resistant cell lines and in the cell line of the national cancer institute's anticancer drug screen panel. Biochem Pharmacol 52:1855-1865, 1996.
20. Giacchetti S, Perpoint B, Zidani R, et al: Phase III multicenter randomized trial of oxaliplatin added to chronomodulatedfl uorouracil-leucovorin as fi rst-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18:136-147. (Pubitemid 30036347)
21. Tournigand C, Cervantes A, Figer A, et al: OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop- and-Go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol. 2006; 24:394-400. (Pubitemid 46630458)
22. Cheeseman SL, Joel SP, Chester JD, Wilson G, Dent JT, Richards FJ, Seymour MT: A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer 2002; 87(4):393-399. (Pubitemid 34983562)
23. Seymour MT, Maughan TS, Ledermann JA,et al: Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomized controlled trial The Lancet 2007; 370:143-152.
24. Shimizu T, Satoh T, Tamura K, et al: Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer:post-approval Japanese population experience. Int J Clin Oncol 2007; 12:218-223. (Pubitemid 46944639)
25. Fuse N, Doi T, Ohtsu A, Takeuchi S, Kojima T, Taku K, et al: Feasibility of Oxaliplatin and Infusional fluorouracil/ leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer. Jan J Clin Oncol 2007; 37(6):434-439. (Pubitemid 47249480)